Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 17 July 2026Incoming appointee
1 itemScheduled Appointment Date1 August 2026
Brian Barry
Previous positionVice President, Clinical and Regulatory Solutions, Medtronic plc (currently in office)
New positionExecutive Officer and Chief Quality Officer (Chief Quality and Regulatory Officer)
生年月日 22 August 1959入社年 2026 (scheduled to join Olympus Corporation of the Americas)所有株式数 0 shares (as of the end of March 2026)
Departing officer
1 itemBoris ShkolnikStepping down
Former PositionExecutive Officer and Chief Quality Officer (Chief Quality and Regulatory Officer)
Reason for change
Boris Shkolnik has led the development of global quality functions and systems as the company strengthens its position as a true medtech company. The next stage of the company's quality transformation will be led by his successor, Brian Barry.
| Item | Details |
|---|---|
| Resolution date | 17 July 2026 |
| Scheduled Appointment Date | 1 August 2026 |
| Name of appointee | Brian Barry |
| Appointee's new position | Executive Officer and Chief Quality Officer (Chief Quality and Regulatory Officer) |
| Appointee's previous position | Vice President, Clinical and Regulatory Solutions, Medtronic plc (currently in office) |
| Appointee's date of birth | 22 August 1959 |
| Year the appointee joined the Company | 2026 (scheduled to join Olympus Corporation of the Americas) |
| Number of shares held by the appointee | 0 shares (as of the end of March 2026) |
| Name of departing officer | Boris Shkolnik |
| Former position of departing officer | Executive Officer and Chief Quality Officer (Chief Quality and Regulatory Officer) |
| Reason for change | Boris Shkolnik has led the development of global quality functions and systems as the company strengthens its position as a true medtech company. The next stage of the company's quality transformation will be led by his successor, Brian Barry. |
Items this document does not state (10)
Date of departureNew position of departing officerReason for departureWhether the incumbent will remain in officeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Brian Barry will lead the next stage of the quality transformation spearheaded by Boris Shkolnik. The company explained that it will strengthen its quality systems, improve patient safety and reinforce its quality culture.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.